Abbott, AstraZeneca Riding Crestor Wave With Expanded Partnership
Executive Summary
Abbott's deal with AstraZeneca to co-promote Crestor offers a chance for the firms to test drive their marketing relationship well in advance of the potential approval of an experimental combination fenofibrate/statin product they are developing together
You may also be interested in...
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011
TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011